 The Data Monitoring Committee DMC has recommended Biophytis SA NASDAQ: BPTS to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after reviewing of safety data. The COVA clinical program is assessing Sarconeos BIO101 in patients aged 45 and older hospitalized with severe respiratory manifestations of COVID-19. 